Embracing model-based designs for dose-finding trialsSharon Love, Victoria Cornelius, James Matcham et al.|British Journal of Cancer|2017Cited by 68
Abstract 2398: Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinicDarren Hodgson, Mark J. O’Connor, Helen Mason et al.|Cancer Research|2014Cited by 7
8LBA Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinicDarren Hodgson, M.J. O’Connor, H.D. Mason et al.|European Journal of Cancer|2014Cited by 0